What were Biomerica's (NASDAQ: BMRA) financial results for Q3 fiscal 2026?

Biomerica reported consolidated net sales of $0.99 million for Q3 fiscal 2026, a slight decline from $1.12 million in the prior year. The decline was mainly due to a planned transition away from lower-margin contract manufacturing. However, the company saw significant growth in its international markets, particularly in Europe.

What is Biomerica's strategic shift in its business model?

Biomerica is shifting its focus toward higher-margin diagnostic therapies, such as its inFoods® IBS product, in response to declining revenue from contract manufacturing. This strategy is aimed at improving profitability and expanding its product offerings in the diagnostics space.

How did Biomerica's international revenue perform in Q3 2026?

Biomerica's international revenue grew by 45% year-over-year, driven by the first commercial orders for its H. pylori test (Hp Detect™) from one of Europe's largest clinical laboratory chains, following MHRA registration in the United Kingdom.

What are the key findings from Biomerica’s real-world data for its inFoods® IBS therapy?

Real-world data showed that nearly 60% of IBS patients using the inFoods® therapy achieved clinically meaningful reductions in abdominal pain, highlighting the product's effectiveness in managing symptoms for patients with irritable bowel syndrome.

Image for illustrative purposes only. Not a real photo.

Biomerica reports Q3 results as Medicare $300 rate anchors commercial pivot

Written by Brie CarterPublished Apr 14, 2026, 12:00 AMLast Updated Jul 6, 2026, 10:30 AM

Biomerica (NASDAQ:BMRA) reported its third-quarter fiscal 2026 financial results today, emphasizing a strategic shift toward higher-margin diagnostic therapies despite a slight decline in top-line revenue.

The period, which ended February 28, 2026, was marked by significant regulatory milestones for the company’s flagship inFoods® IBS product and accelerating traction in European markets.

A primary highlight of the quarter was the implementation of a $300 national Medicare payment rate for the inFoods® IBS test, effective January 1, 2026.

This pricing determination by the Centers for Medicare & Medicaid Services (CMS) establishes a clear reimbursement benchmark, which the company expects will expand patient access and serve as a foundation for negotiations with private insurers.

The inFoods® IBS platform identifies specific food triggers that exacerbate symptoms in patients with irritable bowel syndrome.

While consolidated net sales for the quarter fell to $0.99 million, compared to $1.12 million in the prior year, the decline was largely attributed to a planned transition away from lower-margin contract manufacturing.

Conversely, the company’s international footprint expanded significantly, with European revenue rising 45% year-over-year.

This growth was bolstered by the first commercial orders for the company’s H. pylori test (Hp Detect™) from one of Europe's largest clinical laboratory chains following MHRA registration in the United Kingdom.

Meanwhile, operational discipline remained a core focus, with research and development (R&D) expenses decreasing 24% year-to-date.

This reduction reflects the company’s reallocation of resources from product development toward active commercialization and market access.

Despite these efforts, Biomerica reported a net loss of $1.31 million for the quarter, or $0.44 per share, as it continues to navigate the costs associated with its multi-product launch.

The company also highlighted recent real-world data showing that nearly 60% of IBS patients using the inFoods® therapy achieved clinically meaningful reductions in abdominal pain.